72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Autor: Malaba, Thokozile R, Nakatudde, Irene, Kintu, Kenneth, Colbers, Angela, Chen, Tao, Reynolds, Helen, Read, Lucy, Read, Jim, Stemmet, Lee-Ann, Mrubata, Megan, Byrne, Kelly, Seden, Kay, Twimukye, Adelline, Theunissen, Helene, Hodel, Eva Maria, Chiong, Justin, Hu, Nai-Chung, Burger, David, Wang, Duolao, Byamugisha, Josaphat, Alhassan, Yussif, Bokako, Sharon, Waitt, Catriona, Taegtmeyer, Miriam, Orrell, Catherine, Lamorde, Mohammed, Myer, Landon, Khoo, Saye, Boffito, Marta, Clayden, Polly, Peto, Tim, Pozniak, Anton, Taylor, Graham, Kambugu, Andrew, Ayabo, Tabitha, Kitaka, Sabrina Bakeera, Byakika-Kibwika, Pauline, Kiiza, Daniel, Kyohairwe, Isabella, Laker, Eva, Luswata, Andrew, Magoola, Johnson, Mayanja, Hamza, Najujuma, Flavia Vivian, Nakijoba, Ritah, Namuddu, Diana, Namuli, Teopista, Ntuyo, Peter, Onzia, Annet, Sempijja, Emmanuel, Tabwenda, Jovia, William, Baluku, Abrahams, Nina, Magano, Phakamani, Delport, Carmen, Hlwaya, Linda, Mehta, Ushma, Molitsane, Dineo, Odayar, Jasantha, Tambula, Sivuyile, Tyam, Mbuviswa, Venfolo, Olga, Allerton, Joanna, Nkonyana, Thozama, Mqaba, Sibongile, Else, Laura, Potter, Steve, Neary, Anne
Zdroj: The Lancet HIV; August 2022, Vol. 9 Issue: 8 pe534-e543, 10p
Abstrakt: Late initiation of antiretrovirals in pregnancy is associated with increased risk of perinatal transmission and higher infant mortality. We report the final 72-week postpartum results for efficacy and safety of dolutegravir-based compared with efavirenz-based regimens in mothers and infants.
Databáze: Supplemental Index